好色先生

好色先生

Explore the latest content from across our publications

Log In

Forgot Password?
Create New Account

Loading... please wait

Abstract Details

Characteristics and Outcomes of Mechanical Thrombectomy in Nonagenarians
Cerebrovascular Disease and Interventional Neurology
P2 - Poster Session 2 (5:30 PM-6:30 PM)
3-006

Demonstrate efficacy of mechanical thrombectomy (MT) in large vessel occlusion acute ischemic strokes (LVO AIS), in >90 years old (yo).

Although trials have demonstrated efficacy of MT in LVO AIS, there is dearth of literature on outcomes in nonagenarians.

Between February 2015 and June 2017, 180 patients (N=162 in ≤90yo; N=18 in >90yo), who underwent MT for LVO AIS were retrospectively analyzed for baseline characteristics, cerebrovascular risk factors, atrial fibrillation (AF) rates, anticoagulant use, intravenous thrombolysis rate, door-to-groin puncture (DTG) times, recanalization rate, hemorrhagic conversion rate, NIH stroke scale (NIHSS) score, and discharge modified Rankin score (mRS).

Between the two groups (≤90yo vs. >90yo), there were no major differences in baseline characteristics, cerebrovascular risk factors, or AF rates (49.7% vs. 61.1%; p=0.36). There was significant difference in baseline anticoagulation use (19.8% vs. 0%; p=0.038), despite 55% (6/11) patients in >90yo had prior AF diagnosis. There were no major differences in proportion of patients receiving intravenous thrombolysis, in DTG times, or in patients achieving ≥TICI 2b recanalization. There was no difference in hemorrhagic conversion rate (30.9% vs. 22.2%; p=0.45), although a higher proportion of patients in >90yo trended to higher symptomatic hemorrhage (sICH) rate (32% vs. 75%; p =0.086). There were no major differences in baseline NIHSS or NIHSS at 24-36 hours post-MT. There was also a trend in >90yo requiring more passes during MT (1.7±1.1 vs. 2.2±1.3; p=0.09). Finally, there was no significant difference between good functional outcome (i.e. discharge mRS ≤3) rates. Notably, zero patients in the >90yo had discharge mRS ≤2.

These findings suggest that including discharge mRS=3 as part of the good functional outcome definition in very elderly patients >90yo could allow for a justified increase in MT. Evidence exists for similar recanalization and hemorrhagic conversion rates vs. ≤90yo, with possibly higher sICH rate, in this population.

Authors/Disclosures
Sishir Mannava, MD (UT Health)
PRESENTER
Dr. Mannava has nothing to disclose.
Vasu Saini, MD Dr. Saini has nothing to disclose.
Nida Akram, MBBS (UConn) No disclosure on file
No disclosure on file
Dileep R. Yavagal, MD, FAAN (University of Miami Miller School of Medicine) Dr. Yavagal has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Vascular Dynamics. Dr. Yavagal has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Guidepoint. The institution of Dr. Yavagal has received personal compensation in the range of $500-$4,999 for serving as a Consultant for GLG. Dr. Yavagal has received personal compensation in the range of $0-$499 for serving as a Consultant for Medtronic. Dr. Yavagal has received personal compensation in the range of $0-$499 for serving as a Consultant for Cerenovus/Johnson & Johnson. Dr. Yavagal has received personal compensation in the range of $0-$499 for serving as a Consultant for Stryker. Dr. Yavagal has received personal compensation in the range of $0-$499 for serving as a Consultant for Poseydon. Dr. Yavagal has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Athersys. Dr. Yavagal has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Gravity Medical Technology. Dr. Yavagal has received personal compensation in the range of $0-$499 for serving on a Scientific Advisory or Data Safety Monitoring board for Poseydon. Dr. Yavagal has stock in Poseydon. Dr. Yavagal has stock in Galaxy Therapeutics. Dr. Yavagal has stock in Stentrode. Dr. Yavagal has stock in Gravity Medical. Dr. Yavagal has stock in Gravity Medical Technology. Dr. Yavagal has stock in Athersys. Dr. Yavagal has stock in Rapid Medical . Dr. Yavagal has received intellectual property interests from a discovery or technology relating to health care. Dr. Yavagal has received personal compensation in the range of $5,000-$9,999 for serving as a Medicolegal Expert with Royal Carribean Cruise Line. Dr. Yavagal has received personal compensation in the range of $5,000-$9,999 for serving as a Medicolegal Consultant with Carnival Cruise Line.
Amer Malik, MD (University of Miami Miller School of Medicine) Dr. Malik has nothing to disclose.